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Background. Transforming growth factor-b (TGF-b) has been
implicated in the pathogenesis of a number of kidney diseases
characterized by glomerulosclerosis and tubulointerstitial fibrosis.
TGF-b is secreted in a latent form requiring extracellular modi-
fication to become biologically active. TGF-b inducible gene-h3
(big-h3) is a recently identified TGF-b-induced gene product. The
present study sought to examine big-h3 expression in normal and
diabetic rats.
Methods. big-h3, TGF-b1 and a1 (IV) collagen gene expression
were assessed by Northern blot analysis and in situ hybridization
in 20 Sprague Dawley rats, randomly assigned to receive strepto-
zotocin (diabetic, N 5 11) or citrate buffer alone (control, N 5 9)
and sacrificed eight months later. The effect of exogenous
TGF-b1 on big-h3 expression was also assessed in cultured
proximal tubular cells.
Results. In situ hybridization localized big-h3 gene expression to
the juxtaglomerular apparatus and the pars recta (S3 segment) of
proximal tubules in both control and diabetic animals. Kidney
TGF-b1, big-h3 and a1 (IV) collagen mRNA from diabetic rats
were increased two- to threefold compared with controls (P ,
0.01). There was a significant correlation between TGF-b1 and
big-h3 gene expression in kidneys from diabetic rats (r 5 0.73, P 5
0.01). In addition, big-h3 mRNA increased in response to exog-
enous TGF-b1 in a dose-dependent fashion in cultured proximal
tubular cells.
Conclusion. These findings support the hypothesis that biolog-
ically active TGF-b plays a pathogenetic role in diabetic kidney
disease and suggest that big-h3 may be a useful index of TGF-b1
bioactivity in the kidney.
Transforming growth factor-b (TGF-b) has been impli-
cated in the pathogenesis of a number of kidney diseases
characterized by glomerulosclerosis and tubulointerstitial
fibrosis [1]. Of the three mammalian forms of TGF-b,
TGF-b1 has been the most widely implicated in tissue
fibrosis [2]. TGF-b1 is synthesized as a 391 amino acid
precursor molecule with little biological activity. In tissues
TGF-b1 is found as a homodimer that may be associated
with a TGF-b binding protein. This latent TGF-b1 complex
is present in extracellular matrix [3] where it may be
activated by cleavage of its N-terminal latency associated
peptide (LAP) to yield mature dimeric TGF-b1 [4]. The
mechanisms by which this activation occurs are uncertain
but may include both enzymatic [5] and non-enzymatic
mechanisms [6]. In addition to the complexities of TGF-b
activation its biological effects may also be modified by the
presence of the proteoglycan decorin [7] and the scaveng-
ing protein a2-macroglobulin [8]. Thus, increased TGF-b1
mRNA or protein may not necessarily reflect parallel
changes in TGF-b1 biological activity leading to the use of
TGF-b1 bio-assays in some experimental studies. These
bio-assays include the measurement of TGF-b’s growth
inhibitory effects on mink lung epithelial cells [9] or its
ability to influence the splicing pattern of fibronectin
transcripts [10]. More recently, the activity of TGF-b1 has
been assessed in human [11] and rat vessels [12] by the
measurement of big-h3 (transforming growth factor-b-
inducible gene h3), a novel TGF-b induced gene product
identified by differential hybridization [13].
The present study sought to determine whether big-h3 is
expressed in the rat kidney and to examine its relationship
with TGF-b expression in controls animals and in rats with
experimental diabetes. Diabetes was chosen as a model in
which to study the relationship between TGF-b and big-h3
since several in vitro, animal and human studies suggest that
glucose induces expression of biologically active TGF-b
[14]. Furthermore, because recent studies have indicated
that the proximal tubule may be an important site of
TGF-b and extracellular matrix protein expression in ex-
perimental diabetes [15, 16], this study also sought to
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determine the effect of exogenous TGF-b on big-h3 tran-
scription in cultured proximal tubular cells.
METHODS
Animals
Twenty male Sprague Dawley rats, aged eight weeks and
weighing between 200 and 250 grams, were randomly
assigned to receive streptozotocin (STZ, N 5 11) at a dose
of 45 mg/kg (diabetic) or citrate buffer alone (control, N 5
9). All rats were given free access to standard chow
containing 20% protein (Clark, King & Co, Melbourne,
Australia). Only STZ-treated animals with plasma glucose
levels . 15 mmol/liter were considered diabetic and in-
cluded in the study. Animals were sacrificed at eight
months. Diabetic animals were treated with 6 units insulin
zinc suspension (Ultratard HM; Novo Nordisk, Bagsvaerd,
Denmark) injected subcutaneously three times per week to
maintain body weight and improve long-term survival. For
24 hours prior to sacrifice, rats were housed in metabolic
cages for subsequent measurement of urinary albumin
excretion using a coated tube radioimmunoassay [17].
Immediately prior to sacrifice, rats were weighed. Animals
were sacrificed by decapitation and blood collected for
determination of plasma glucose by glucose oxidase tech-
nique [18] and hemoglobin A1 by high performance liquid
chromatography (HPLC) [19]. The left kidney was re-
moved and bissected sagitally. The anterior half-kidney was
immersion fixed in 10% neutral buffered formalin for in
situ hybridization and the posterior half was immersed in
Methyl Carnoy’s fixative for immunohistochemical studies.
The right kidney was snap frozen in liquid nitrogen and
subsequently stored at 280°C for later Northern analysis.
Patients
For in vitro studies human proximal tubular cells (PTC)
were used. Segments of macroscopically and histologically
normal renal cortex were obtained aseptically from three
adult human kidneys removed surgically because of small
(,6 cm) renal adenocarcinomas. The ages (sex) of the
patients were 21 (male), 44 (male) and 72 (female). Pa-
tients were otherwise healthy and were receiving no med-
ications. Informed consent was obtained prior to each
operative procedure, and the use of human renal tissue for
primary culture was approved by the Royal North Shore
Hospital and University of Sydney Human Medical Re-
search Ethics Committee.
Cell culture
Primary cultures of human proximal tubular cells (PTC)
were obtained using previously described methods [20].
Briefly, renal cortical tissue was dissected from the medulla,
minced, digested with collagenase (class 2, 383 U/mg;
Worthington, Freehold, NJ, USA) and passed through a
100 mm mesh. Filtered tissue was resuspended in 45%
Percoll (Pharmacia, Uppsala, Sweden) and separated into
four distinct bands by isopyenic ultracentrifugation. The
lowermost band was removed for PTC culture and resus-
pended in serum-free, antibiotic-free, hormonally-defined
media, consisting of 1:1 (vol/vol) Dulbecco’s modified
Eagle’s media and Ham’s F-12 (DMEM/F-12; ICN Phar-
maceuticals Inc., Costa Mesa, CA, USA), supplemented
with 5 mg/ml human transferrin (Sigma, St. Louis, MO,
USA), 5 mg/ml (0.87 mM) bovine insulin (Sigma), 0.05 mM
hydrocortisone (Sigma), 10 ng/ml (1.64 nM) epidermal
growth factor (Collaborative Research Inc., Bedford, MA,
USA), 50 mM prostaglandin E1 (Sigma) and 5 pM tri-
iodothyronine (Sigma). The tubular fragments were plated
at a density of 1.5 mg pellet/cm2 (approximately 5000 to
7000 fragments/cm2) in 75 cm2 flasks (Corning, New York).
Media were changed every 48 hours. The cells were incu-
bated in humidified 95% air/5% CO2 at 37°C and were
subcultured at near-confluence using seeding densities of
4000 cells/cm2. Such cells were designated passage 1.
Cytologic examination of PTC preparations from all donors
failed to reveal any evidence of cellular atypia. The ultra-
structural, growth and transport characteristics of these
cells and their responses to hormonal and cytokine stimu-
lation have been previously studied and found to reproduc-
ibly exhibit the features of PTC in vivo [20].
Experimental protocol
Northern blot analyses were performed on confluent,
quiescent, passage 2 human PTC grown in 6 cm diameter
Petri dishes (Nunc, Roskilde, Denmark). Quiescence was
achieved by incubation for 24 hours in basic media
(DMEM/Ham’s F-12 containing 5 mg/ml human trans-
ferrin). Cells were then incubated for 24 hours with basic
media containing either vehicle (control) or various con-
centrations (0.1, 1.0 and 10 ng/ml) of TGF-b1 (Sigma). The
concentrations of TGF-b1 employed were based on previ-
ous dose-response studies in these cells [21]. To determine
the specificity of action of TGF-b1 on big-h3 expression,
additional experiments were performed in which confluent,
quiescent PTC were incubated for 24 hours with 100 ng/ml
epidermal growth factor (EGF), 100 ng/ml insulin-like
growth factor-I (IGF-1) or appropriate vehicles (controls).
These cytokines were selected as they have both been
shown, at the concentration used, to be potent stimulators
of proximal tubular cell growth [22, 23] and matrix expres-
sion [24, 25] and have also been shown to be increased in
the kidney in experimental diabetes [26, 27].
Northern analysis
Kidneys stored at 280°C were homogenized (Ultra-
Turrax; Janke and Kunkel, Staufen, Germany) and total
RNA was isolated by the acid guanidinium thiocyanate-
phenol-chloroform extraction method [28]. RNA purity
and concentration were determined spectrophotometri-
cally. Twenty microgram samples were denatured and
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electrophoresed through 0.8% agarose formaldehyde gels.
RNA integrity was verified by examination of the 28S and
18S ribosomal RNA bands of ethidium bromide stained
material under ultraviolet light. RNA was then transferred
onto nylon filters (Hybond-N, Amersham, UK) by capillary
action and fixed by ultraviolet irradiation.
Filters were hybridized with a 2055 bp cDNA probe
coding for human big-h3 (gift of Dr. K. Bennett, Bristol-
Myers Squibb, Seattle, WA, USA), a 985 bp cDNA probe
coding for rat TGF-b1 (gift of Dr. Qian, NIH, Bethesda,
MD, USA) and a 1.8 kb cDNA probe coding for mouse a1
(IV) collagen [a(1) IV col; gift of Dr. R. Timpl, Max Plank,
Martinsried, Germany]. cDNA probes were labeled with
[a-32P] dCTP (DuPont, Boston, MA, USA) by random
primed DNA synthesis (Boehringer Mannheim, Mann-
heim, Germany). Hybridization of filters was performed at
42°C for 24 hours in 50% formamide, 45 mM Na2HPO4, 5 3
Denhardt’s solution, 0.5% SDS and sonicated salmon
sperm DNA. Filters were then washed in solutions of
decreasing ionic strength and increasing temperature. The
final stringency was 0.1 3 standard saline citrate (SSC) with
0.1% SDS for 20 minutes at 42°C. Intensity of hybridization
was quantified by scanning densitometry (LKB Ultroscan
XL, Bromma, Sweden). To control for differences in RNA
loading and transfer filters were hybridized with an oligo-
nucleotide probe for 18S rRNA end-labeled with [a-32P]
dCTP (DuPont) by terminal transferase (Boehringer
Mannheim). Results were expressed as the ratio of image
intensity of mRNA to 18S rRNA relative to control kidneys
which were arbitrarily assigned a value of 1.
In situ hybridization
The cDNA probe for big-h3 was cloned into pBluescript
KS1 (Stratagene) and linearized with HindIII and XbaI to
produce an antisense riboprobe with T3 RNA polymerase.
In situ hybridization was performed as previously described
[29]. In brief, 4 mm thick sections cut from formalin-fixed
paraffin-embedded kidney tissue were placed onto slides
precoated with 3-aminopropyltriethoxysilane and baked
overnight at 37°C. Tissue sections were dewaxed and
rehydrated in graded ethanol and milliQ water, equili-
brated in P buffer (50 mM Tris-HCl, pH 7.5, 5 mM EDTA)
and incubated in 125 mg/ml Pronase E in P buffer for 10
minutes at 37°C. Sections were then washed in 0.1 M
sodium phosphate buffer (pH 7.2), briefly refixed in 4%
paraformaldehyde for 10 minutes, rinsed in milliQ water,
dehydrated in 70% ethanol and air dried. Hybridization
buffer containing 2 3 104 cpm/ml riboprobe in 300 mM
NaCl, 10 mM Tris-HCl (pH 7.5), 10 mM Na2HPO4, 5 mM
EDTA (pH 8.0), 13 Denhardt’s solution, 50% formamide,
17 mg/ml yeast RNA, 10% wt/vol dextran sulfate was
heated to 85°C for five minutes. Twenty-five microliters of
this solution were then added to each section. Hybridiza-
tion was performed overnight at 60°C in 50% formamide
humidified chambers. Sections hybridized with sense probe
for big-h3 were used as controls for non-specific binding.
After hybridization, slides were washed in 2 3 SSC con-
taining 50% formamide prewarmed to 50°C to remove
coverslips. Sections were then washed in the above solution
for one hour at 55°C, rinsed three more times in RNAse
buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, pH 8.0, 0.5
M NaCl) and then incubated with RNAse A (150 mg/ml) for
one hour at 37°C. Sections were later washed in 2 3 SSC
for 45 minutes at 55°C, dehydrated in graded ethanol, air
dried and exposed to Kodak X-Omat autoradiographic film
for one to three days. Slides were then dipped in Ilford K5
nuclear emulsion (Ilford, Mobberley, Cheshire, UK),
stored in a light-free box with desiccant at room tempera-
ture for two to three weeks, immersed in Kodak D19
developer, fixed in Ilford Hypam and stained with hema-
toxylin and eosin or periodic acid-Schiff (PAS).
Immunohistochemistry
Four-micrometer thick sections were placed onto slides,
deparaffinized and rehydrated. Sections for type IV colla-
gen immunohistochemistry underwent microwave oven
pretreatment as previously described [30]. To block endog-
enous peroxidase sections were pretreated with 1% H2O2/
methanol. Sections were next incubated in Protein Block-
ing Agent (Lipshaw-Immunon, Pittsburgh, PA, USA) for
20 minutes at room temperature. This was followed by
incubation with polyclonal goat anti-bovine/anti-human
type IV collagen antibody (Southern Biotechnology, Bir-
mingham, AL, USA) for 60 minutes at room temperature,
washing sections in PBS and incubating them with universal
biotinylated immunoglobulin (DAKO, Carpinteria, CA,
USA) and peroxidase-conjugated strepavidin (DAKO) as
previously described [12]. Peroxidase conjugates were sub-
sequently localized using diaminobenzidine tetrahydro-
chloride (DAB) as a chromogen. Sections were then coun-
terstained with Mayer’s hematoxylin and examined by two
independent observers blinded to the disease status of the
animal. Immunostaining was scored using a scale of 0 to 3
where 0 5 no staining and 3 5 maximum staining (adapted
from [15]). Negative controls included omitting the primary
antibody or replacing it with normal rabbit IgG at an
equivalent protein concentration.
Statistics
Because of a positively skewed distribution albuminuria
was logarithmically transformed before statistical analysis.
Results are expressed as mean 6 SEM unless stated other-
wise. Data derived from immunohistochemical studies were
not normally distributed and were analyzed non-paramet-
rically using the Mann-Whitney U-test. All other compari-
sons between control and diabetic groups were analyzed by
ANOVA with correction for multiple comparisons using
the Fisher’s least significant difference test. Correlation was
examined by linear regression analysis. Analyses were
performed using the Statview SE1 Graphics package
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(Abacus Concepts, Calabasas, CA, USA) on an Apple
Macintosh Quadra 605 (Apple Computer Inc, Cupertino,
CA, USA). A P value # 0.05 was considered statistically
significant.
RESULTS
Animal characteristics
Plasma glucose and HbA1 confirmed the presence of
diabetes in all STZ-treated rats (Table 1). Diabetes was
associated with reduced body mass and increased blood
pressure when compared with control animals (Table 1).
The albumin excretion rates were at least tenfold higher in
diabetic compared with non-diabetic animals (Table 1).
Northern analysis: In vivo studies
Kidney TGF-b1 and big-h3 mRNA from diabetic rats
were both increased approximately twofold compared with
their non-diabetic counterparts (Figs. 1 and 2). A signifi-
cant correlation between TGF-b1 and big-h3 gene expres-
sion was present in kidneys from diabetic (r 5 0.73, P 5
0.01; Fig. 3) and approached statistical significance in
control rats (P 5 0.08). Northern analysis also demon-
strated that type IV collagen mRNA was increased in the
diabetic rat kidney. A close correlation between big-h3 and
a(1) IV collagen mRNA in both control (r 5 0.92, P ,
0.05) and diabetic rat kidneys (r 5 0.79, P , 0.05) was also
noted.
Northern analysis: In vitro studies
Under basal conditions only low levels of big-h3 tran-
script were detected. However, big-h3 mRNA increased in
response to exogenous TGF-b1 in a dose-dependent fash-
ion (Figs. 4 and 5). In contrast, big-h3 mRNA was un-
changed in response to either 100 ng/ml EGF or IGF-I
(Fig. 6).
In situ hybridization
In situ hybridization demonstrated big-h3 gene expres-
sion in the outer stripe of the outer medulla (OSOM) and
inner cortex in kidneys of both control and diabetic animals
(Fig. 7). Light microscopic examination of emulsion-dipped
sections revealed that big-h3 mRNA was localized to the
vascular component of the juxtaglomerular apparatus
(JGA) (Fig. 8 A, B) in control and in greater abundance in
diabetic rats. In the outer cortex, glomeruli, proximal and
Table 1. Animal characteristics at end of study period
Control Diabetic
N 9 11
Body weight g 575 6 25 428 6 23b
Blood pressure mm Hg 118 6 2 140 6 3b
Glucose mmol/liter 4.3 6 0.1 24.1 6 1.6b
HbA1c % 1.8 6 0.2 4.8 6 0.2
b
Albuminuria mg/day 2844 6 554 82742 6 16821b
Type IV collagenc 1 (1) 2.5 (1.5–3.0)a
Data are means 6 SEM or median (range).
a P 5 0.05 versus control
b P , 0.001 versus control
c Semiquantitative scoring for immunohistochemistry
Fig. 1. Northern blot of big-h3, TGF-b1, a1 (IV) collagen and 18S in
control and diabetic rat kidneys. Increased gene expression of big-h3 and
TGF-b1 is seen in kidneys of diabetic rats. 18S rRNA is similar in control
and diabetic groups.
Fig. 2. Quantitation of kidney big-h3, TGF-b1 and a1 (IV) collagen
mRNA in control (M) and diabetic (f). Data are means 6 SEM of the ratio
of optical density of big-h3, TGF-b1 and a1 (IV) col mRNA to that of 18S
rRNA relative to control values (designated an arbitrary value of 1). *P 5
0.05, †P , 0.01, diabetic versus control
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distal tubules, collecting ducts and maculae densa showed
no specific hybridization. Within the proximal tubules
intense big-h3 expression was only present in the inner
cortex (Fig. 8 C, D) and OSOM, the location of the pars
recta (S3). In the inner stripe of the outer medulla and in
inner medulla no specific hybridization was detected. No
difference in the sites of distribution within the kidney
was noted between control and diabetic animals. No
hybridization was detected with big-h3 sense riboprobe
(Fig. 8 E, F).
Immunohistochemistry
Greater immunostaining for type IV collagen was
present in the interstitium of diabetic rats compared with
control animals (P , 0.05; Table 1 and Fig. 9). Tissues
treated with normal rabbit IgG showed no positive staining.
DISCUSSION
The present study demonstrates that big-h3 is constitu-
tively expressed in the vascular component of the juxtaglo-
merular apparatus and in the pars recta (S3 segment) of the
proximal tubule. In addition, big-h3 was overexpressed in
parallel with TGF-b1 in the kidneys of rats with experimen-
tal diabetes.
big-h3 is a 683 amino acid secreted protein that was
recently cloned from a human adenocarcinoma cell line
that had been treated with TGF-b1 and screened by
differential hybridization [13]. The mature protein contains
a secretory sequence in its NH2 terminus, four homologous
internal domains and an integrin recognition sequence
(arg-gly-asp) at its carboxyl end [13]. Sequence analysis of
big-h3 demonstrates significant evolutionary conservation
with 91% homology at the amino acid level between murine
and human forms of the protein [31]. While the primary
structure of big-h3 is unique, it does have regions of
homology with insect fascilin-I and Mycobacterium bovis
MPB70 [13].
The physiological functions of big-h3 are not well under-
stood though preliminary investigations suggest that it may
modulate tumor formation and cell adhesion [31, 32].
Indeed, recent studies suggest that big-h3 may be an
extracellular matrix microfibril-associated protein (MP 78/
80) that binds to the microfibrillar proteins fibrillin-I and
MAGP-1 [33]. In vitro, increased big-h3 expression in
response to TGF-b has been demonstrated in a variety of
cell lines including mammary epithelial cells, fibroblasts
and keratinocytes [31]. In vivo, big-h3 has been found in the
papillary dermis [32], corneal epithelium [34] and blood
vessels [11, 12].
Investigation of the role of TGF-b in diabetic kidney
disease has largely focused on the glomerulus, although the
tubulointerstitium also undergoes significant structural
damage [35]. In vitro, exposure of proximal tubular cells to
high glucose concentrations leads to increased TGF-b1 and
collagen expression [36] as it does in mesangial cells [37].
Indeed, TGF-b1 is found throughout the nephron includ-
ing the pars recta of the proximal tubule [38] and receptors
for TGF-b are ubiquitously expressed [39]. Thus, the close
proximity of ligand and receptor in the region of the
proximal tubule (as at many other sites) is consistent with a
paracrine action of TGF-b with a high glucose-mediated
elevation in TGF-b1 leading to increased expression of the
TGF-b inducible gene big-h3, as demonstrated in the
present study. The mechanisms underlying the restricted
pattern of big-h3 expression are not understood, though
highly localized patterns of gene transcription in the kidney
are well described [40] and presumably reflect the various
cell phenotypes within the nephron.
As with diabetic nephropathy in humans, experimental
diabetes is associated with increased extracellular matrix
deposition as indicated in the present study by the in-
creased gene expression and tissue deposition of type IV
collagen. While TGF-b stimulates the synthesis of extracel-
lular matrix and, in general, inhibits cell proliferation, it is
not the only growth factor with these actions [41]. Further-
more, the complexities of TGF-b activation following its
secretion have led to various strategies of assessing its
biological activity. For instance, since TGF-b1 causes pref-
erential expression of certain alternatively spliced isoforms
of fibronectin mRNA [42], measurement of such transcripts
has been used to assess TGF-b1 biological activity [10].
However, this alternative splicing of fibronectin mRNA is
not unique to TGF-b1 but is also found in response to
Fig. 3. Correlation between big-h3 and TGF-b mRNA in control (E) and
diabetic (F) rat kidneys.
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other growth factors such as retinoic acid and 1,25-dihy-
droxy vitamin D3 [43]. The growth inhibitory action of
TGF-b on mink lung epithelial cell 3H-thymidine incorpo-
ration has also been used as a TGF-b bioassay [9]. How-
ever, other growth factors such as hepatocyte growth factor
(HGF) may release these cells from the growth inhibitory
effects of TGF-b [44]. This may be particularly relevant to
diabetes where in vitro and in vivo studies indicate in-
creased expression of many pro-proliferative growth factors
including HGF [45, 46]. In the present study diabetes was
associated with increased expression of both TGF-b1 and
big-h3. In addition, there was a significant correlation
between TGF-b1 and big-h3 and between big-h3 and a(1)
IV collagen mRNA consistent with translation of TGF-b1
to biologically active protein. Furthermore, a dose-depen-
dent relationship between the magnitude of big-h3 expres-
sion and the concentration of TGF-b1 in cultured proximal
tubular cells was also noted. In contrast, epidermal growth
factor (EGF) and insulin-like growth factor-I (IGF-I), two
cytokines that are potent stimulators of proximal tubular
cell growth [22] and matrix synthesis [24, 25] and have also
been shown to be increased in the kidney in experimental
diabetes [26, 27] did not affect big-h3 expression. These
findings suggest that big-h3 may be useful as an index of
TGF-b1 bioactivity in the kidney as well as in blood vessels
[11, 12]. However, while the expression of big-h3 is linked
to TGF-b bio-activity, and its expression was unaffected by
EGF or IGF-I, it remains to be established whether induc-
tion of expression of big-h3 is exclusively TGF-b-depen-
dent and whether the measurement of big-h3 gene expres-
sion is superior to more conventional methods of assessing
TGF-b bio-activity.
Within the renal cortex big-h3 gene expression was
Fig. 4. Northern blot of big-h3 gene expression
in cultured proximal tubular cells exposed to
TGF-b1 at concentrations of 0 to 10 ng/ml. big-
h3 mRNA increased in response to exogenous
TGF-b1 in a dose-dependent fashion. 18S
rRNA expression was unchanged.
Fig. 5. big-h3 gene expression in cultured proximal tubular cells exposed
to TGF-b1 at concentrations of 0 to 10 ng/ml. Data are means 6 SE of the
ratio of optical density of big-h3 to that of 18S rRNA relative to control
values (designated an arbitrary value of 1). *P , 0.05 versus control, †P ,
0.05 versus 0.1 ng/ml.
Fig. 6. big-h3 gene expression in cultured proximal tubular cells exposed
to EGF and IGF-I 100 ng/ml. Data are means 6 SE of the ratio of optical
density of big-h3 to that of 18S rRNA relative to control values (desig-
nated an arbitrary value of 1).
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localized to the juxtaglomerular apparatus (JGA). This
region of the nephron, which links the distal end of the
thick ascending limb of the loop of Henle to the vascular
pole of the glomerulus, is intimately involved with the
regulation of tubuloglomerular feedback, glomerular cap-
illary pressure and renin secretion [47]. Within the JGA,
big-h3 mRNA was not present in the macula densa, but was
found exclusively in cells of the vascular component. These
highly specialized cells are the source of various vasoactive
factors including renin [48], angiotensin II [49] and nitric
oxide synthase [50]. In addition, expression of both TGF-b1
[51] and platelet-derived growth factor (PDGF) [52] have
been demonstrated in the vascular cells of the JGA in
cyclosporine-induced nephrotoxic injury, and increased
TGF-b2 has also been found in the JGA in response to
volume [53] and potassium depletion [54]. Interaction
between vasoactive factors and TGF-b has also been
suggested by the ability of TGF-b to stimulate renin release
[55] and the action of angiotensin II in increasing TGF-b
expression [56]. Indeed, experimental diabetes is associated
with both increased expression of renin [57] and TGF-b1
[10, 16] in the kidney.
big-h3 was also expressed in the inner cortex and outer
stripe of the outer medulla where it was found exclusively in
proximal tubular cells as identified morphologically by their
cuboidal shape, eosinophilic cytoplasm and brush border.
These proximal tubules at the outer stripe of the outer
medulla are almost exclusively the S3 segment or pars recta
[58]. The physiological significance of the restricted expres-
sion of big-h3 to this part of the nephron is uncertain. The
pars recta of the proximal tubule may be particularly
vulnerable to nephrotoxic and ischemic injury as a conse-
quence of tubular concentration, interstitial hypertonicity
and low oxygen tension [59]. This has led to the suggestion
that ischemic peritubular microangiopathy in diabetes may
preferentially affect the pars recta of the proximal tubule
[60]. In a study of extracellular matrix gene expression in
STZ-diabetes, Ihm and colleagues reported increased gene
expression of a1 (IV) collagen predominantly in the prox-
imal tubules of the deep cortex and outer medullary stripe
at 28 but not seven days of diabetes, suggesting that the
described collagen overexpression was a diabetes rather
than a STZ effect [61]. In a recent study of patients with
incipient diabetic nephropathy, Nuyts and coworkers re-
ported a significant correlation between glycated hemoglo-
bin and urinary excretion of the intestinal alkaline phos-
phatase (hIAP), the isoenzyme expressed exclusively by the
pars recta of the proximal tubule [60]. These findings
suggest that increased expression of both hIAP and big-h3
may reflect the response of the pars recta to the metabolic
insult of hyperglycemia. In addition, this segment of the
proximal tubule is also the major intrarenal location of
neutral endopeptidase [62], the enzyme responsible for the
metabolism of atrial natriuretic peptide [63], bradykinin
[64] and endothelin [65]. Indeed, a link between the
intrarenal actions of vasoactive hormones and that of
TGF-b is also suggested by the finding that like big-h3,
renin is constitutively produced only in the juxtaglomerular
Fig. 7. In situ hybridization for big-h3 mRNA in longitudinal sections of control (left panel) and diabetic (right panel) rat kidney localizing gene
expression to the inner cortex and outer stripe of outer medulla.
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apparatus and the proximal tubule [66], and, in particular,
the S3 segment [67]. This interaction between the renin-
angiotensin system and the effects of TGF-b overexpres-
sion may be particularly relevant to diabetic nephropathy
where experimental studies and clinical trials indicate a
beneficial effect of angiotensin converting enzyme inhibi-
tion in reducing TGF-b [16, 68] in addition to ameliorating
the associated structural and functional abnormalities of
diabetic renal disease [16, 69].
In summary, the present study supports the contention
that biologically active TGF-b plays a pathogenetic role in
diabetic kidney disease and suggests that big-h3 may be
useful as an index of TGF-b1 bioactivity in the kidney.
However, the function of big-h3 in renal physiology and its
Fig. 8. In situ hybridization photomicrographs of big-h3 mRNA. In the cortex hybridization is present in the vascular component of the juxtaglomerular
apparatus in control (A) and in greater abundance in diabetic (B) rat kidneys. Glomeruli, tubules and macula densa showed no big-h3 expression. In
both control (C) and diabetic (D) kidneys proximal tubules in the inner cortex but not the outer cortex (A, B) intensely expressed big-h3. No specific
hybridization was detected in sections exposed to big-h3 sense probe (E, F). Magnification 3400.
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actions in various pathological states such as diabetes
remain speculative. Its sites of distribution within the
kidney and its association with TGF-b1 expression raise the
possibility of an interaction between vasoactive factors,
matrix synthesis and the diabetic state.
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APPENDIX
Abbreviations used in this article are: a1-col, a1-collagen; big-h3,
transforming growth factor-b inducible gene-h3; DAB, diaminobenzidine
tetrahydrochloride; EGF, epidermal growth factor; HGF, hepatocyte
growth factor; HPLC, high performance liquid chromatography; IGF-1,
insulin-like growth factor-1; JGA, juxtaglomerular apparatus; OSOM,
outer stripe of the outer medulla; PTC, proximal tubular cells; STZ,
streptozotocin; TGF, transforming growth factor.
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